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Primary malignant melanoma of the urinary bladder is a rare neoplasm, with only 19 cases reported to
date. We present a case report of an 84-year-old woman who underwent transurethral resection of a
mucosal melanoma of bladder origin. She had no previous or concurrent diagnosis of cutaneous mela-
noma. The patient underwent transurethral resection of the tumor 5 months before presentation at our
center with a recurrent, muscle-invasive tumor located in the bladder trigone, with evidence of bone
metastasis. Malignant melanoma of the urinary bladder carries a poor prognosis and poses a therapeutic
challenge to urologists who manage patients with this rare disease.
Published by Elsevier Inc.Open access under CC BY-NC-ND license.Introduction
Primary melanoma of the genitourinary tract is extremely rare
and accounts for less than 0.2% of all melanomas.1 There have been
only 19 cases of primary melanoma arising from the urinary
bladder reported to date. The majority of malignant melanomas of
the bladder are metastatic lesions from a distant primary site, more
commonly of cutaneous origins. Here, we report the 20th case of
primary malignant melanoma of the bladder and review published
literature to describe the epidemiology, clinical features, and
management of this rare and aggressive disease.
Case Presentation
An 84-year-old Caucasian woman with multiple comorbidities
and past history notable for basal cell carcinoma presented to an
outside urologist with complaints of vaginal spotting and gross
hematuria. Outside cystoscopy records indicated a friable proximal
urethral caruncle that impeded the visualization of the urinary
bladder. Biopsy of the mass revealed malignant melanoma.þ1-301-402-0922.
ng).
CC BY-NC-ND license.Physical examinationwas benign and did not reveal any suspicious
skin lesions. The patient underwent a complete transurethral
resection (TUR) of the melanoma of presumed urethral origin.
Final surgical pathology demonstrated nodular invasive malignant
melanoma, with a thickness of at least 5 mm and positive conﬁr-
matory S-100 and Melan-A stains. Subsequently, staging positron
emission tomography/computed tomographic (CT) scans revealed
a cecal mass, thus prompting a right hemicolectomy. On pathologic
examination, the cecal mass was found to be a 5.0-cm adenoma
with microscopic foci of intramucosal adenocarcinoma and nega-
tive regional lymph nodes.
Five months later, the patient presented emergently to our
center with complaints of dysuria, gross hematuria, and urinary
retention. CT scan showed a 3.8-cm lobulatedmass in the posterior
bladder with associated bladder wall thickening, a 1.8-cm urethral
mass, and mediastinal lymphadenopathy (Fig. 1). Mediastinal
biopsy revealed benign lymphoid tissue. Cystoscopy revealed a
>5-cm friable ﬂesh-colored spherical mass arising from thick
ﬁbrovascular stalk emanating from the left hemitrigone. The bulk
of the mass was just proximal to the vesicourethral junction,
obstructing the bladder neck (Fig. 2). There was no urethral scar-
ring or evidence of previous TUR, which conﬁrmed that the mel-
anomawas of bladder neck origin but hadmasqueraded initially as
a urethral mass. An extensive TUR of the tumor was performed to
deep intravesical fat of the trigone. Examination under anesthesia
demonstrated a mobile bladder with induration at the anterior
surface of the vagina. Histopathologic examination of the tumor
Figure 1. Computed tomography of the pelvis with intravenous contrast 5 months
after complete transurethral resection of the tumor showing a malignant melanoma of
the urinary bladder recurring in the bladder trigone.
Figure 3. Histologic appearance of primary melanoma of the bladder. (A) Melanoma
tumor with extensive necrosis, H&E, 4. (B) Malignant melanoma cells showing
multiple mitotic ﬁgures (arrows); H&E, 20.
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evidence of tumor invasion into the bladder wall and perivesical
fat, muscle tissue could not be identiﬁed on histologic slide
because of extensive necrosis (Fig. 3) with presumed erosion
through the muscle layers of the bladder.
The patient recovered uneventfully and experienced complete
resolution of her urologic symptoms. On follow-up CTscan 2weeks
after TUR, the patient was found to have a metastatic lesion and
pathologic fracture at the right inferior pubic ramus. Her case was
discussed at a multidisciplinary conference attended by dedicated
genitourinary and melanoma oncologists. Surgery is not indicated
for this patient who developed cT3N0M1 bladder melanoma.
The patient was tested negative for both BRAF V600 and c-Kit
mutations. She was recommended to undergo immediate immu-
notherapy with ipilimumab for control of disease progression.Figure 2. Cystoscopy performed 6 months from complete transurethral resection of
malignant melanoma (MM) of the bladder recurring at the bladder trigone, obstructing
the bladder neck (BN).Discussion
There have been only 20 cases of primary melanoma of the
urinary bladder reported in the medical literature to date,
including this case report.1 The mean age at diagnosis is 62 years
(range, 34-84), with 75% of all cases diagnosed after 50 years.
Eleven of 20 reported patients were female. The etiology and risk
factors for primary bladder melanoma are unknown. Gross he-
maturia is the most common presenting symptom, which im-
plicates advanced disease. Some patients might also present with
voiding symptoms, such as dysuria, frequency, or urinary reten-
tion on the basis of tumor location and invasiveness.
Cystoscopy and transurethral biopsy is the primary method to
diagnose bladder melanoma. Although primary bladder mela-
noma is rare, metastasis of primary cutaneous melanoma to the
bladder is relatively common, affecting up to 18% of patients who
die from metastatic melanoma.2 Ainsworth et al3 initially pro-
posed criteria to conﬁrm location of the primary lesion. These
criteria require the following: (1) a detailed history and physical
examination of the patient to rule out active or regressed cuta-
neous, ocular, and other visceral primary melanoma, and (2)
conﬁrmation of a pattern of recurrence and local metastasis in
the pelvis, which is consistent with primary bladder tumor rather
than the pattern of widespread metastasis seen in secondary
metastatic melanoma.
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noma.4 We propose that the American Joint Committee on Cancer
tumor, node, and metastasis staging system for bladder tumor
should be applied to bladder melanomas. Clinical staging is
determined by a combination of radiographic assessment for
metastasis, TUR and biopsy of the tumor, and pathologic assess-
ment. It is unknown whether measurements of Breslow thickness
and mitotic rate that are traditionally used to risk stratify cuta-
neous melanoma are applicable in the assessment and manage-
ment of primary bladder melanoma.
Primary melanoma of the bladder seems not to manifest itself
until the disease progresses to advanced stages. Based on our
review of the 20 known cases of primary bladder melanoma, at
least 14 (70%) cases presented with muscle invasive disease.1
Delayed diagnosis combined with locally advanced stage of dis-
ease at diagnosis leads to very poor prognosis, regardless of the
treatment approach. Most patients die of metastatic disease
within 3 years after initial diagnosis.1 The ﬁrst-line treatment of
bladder melanoma is surgery. The options include TUR, partial
cystectomy, and radical cystectomy based on the stage of the
tumor. An important consideration in choosing an appropriate
treatment for a patient is the patient’s overall health status and
life expectancy.
For patients who are poor surgical candidates, radical treatments
should be avoided given signiﬁcant treatment-related morbidities
and the high risk of recurrence, despite aggressive extirpative sur-
gery. It is reasonable to perform TUR of the tumor and administer
immune or chemotherapy according to a patient’s ability to tolerate
medical treatment. Chemotherapy options include platinum-based
regimens such as cisplatin/carboplatin with paclitaxel. Immuno-
therapy options include ipilimumab or, for patients with excellentperformance status, high-dose interleukin 2.5 Inhibitors of onco-
genic BRAF should be considered for patients whose tumors har-
bor a BRAF V600 mutation.5 Radiation therapy has a limited role in
the treatment of cutaneous melanoma, although might be
considered for palliative purposes in patients with primary
bladder melanoma.5
Conclusion
Malignant melanoma of the urinary bladder carries a poor
prognosis and poses a therapeutic challenge to urologists who
manage patients with this rare disease. Patients who present with
suspected or conﬁrmed primary bladder melanoma should be
referred to a center that specializes in the multidisciplinary man-
agement of patients with melanoma.Conﬂict of interest
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